1926172-50-0

Basic information

• Product Name: 4-Bromo-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole
• Synonyms: 4-Bromo-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole
• CAS NO: 1926172-50-0
• Molecular Formula: C13H15BrN2O
• Molecular Weight: 295.175
• Mol File: 1926172-50-0.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 419.1±45.0 °C(Predicted)
• Appearance: /
• Density: 1.55±0.1 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: -0.01±0.30(Predicted)
• CAS DataBase Reference: 4-Bromo-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Bromo-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole(1926172-50-0)
• EPA Substance Registry System: 4-Bromo-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole(1926172-50-0)

Safety Data

• Hazardous Substances Data: 1926172-50-0(Hazardous Substances Data)

Usage

General Description

4-Bromo-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole is a chemical compound with the molecular formula C15H18BrN2O. It is a synthetic indazole derivative and belongs to the class of cannabinoids, which are psychoactive compounds found in cannabis. This particular compound is a potent agonist of the cannabinoid receptors CB1 and CB2, and it has been studied for its potential pharmacological effects, including analgesic, anti-inflammatory, and neuroprotective properties. It has also been identified as a designer drug and has been subject to regulatory control in some countries due to its psychoactive effects. Further research is ongoing to understand its potential medical and recreational applications, as well as its potential risks and side effects.

Upstream product

• 110-87-2 3,4-dihydro-2H-pyran 
• 926922-40-9 4-bromo-5-methyl-1H-indazole 

Downstream Products

• 2022976-34-5 (5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)boronic acid 

Relevant articles and documents

INHIBITORS OF KRAS G12C PROTEIN AND USES THEREOF

Provided are novel compounds useful as inhibitors of the KRAS protein, as well as pharmaceutical compositions comprising these compounds and methods of treatment by administration of these compounds or the pharmaceutical compositions.

Kras-G12C inhibitor heterocyclic compounds

The invention relates to Kras-G12C inhibitor heterocyclic compounds represented by formula I, a preparation method thereof, and application of the Kras-G12C inhibitor heterocyclic compounds in prevention and treatment of tumor diseases such as lung cancer, colorectal cancer and pancreatic cancer. In the preparation process, the compounds of the general formula I are obtained through a series of reactions such as SN2 reaction, protection, coupling reaction, deprotection, condensation reaction and the like.

HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF

The present disclosure relates to inhibitors of one or more isoforms of RAS, such as inhibitors of one or more of KRAS, HRAS and NRAS, or mutants thereof, such as G12D, G12V, G13D or G12C mutants thereof. Therapeutic methods of treating conditions and dis